# Scott D. Solomon

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/scott-d-solomon/

## Facts

| Field | Value |
| --- | --- |
| Citations | 187,597 |
| Field | Heart Failure Treatment and Management |
| h-index | 190 |
| i10-index | 1,139 |
| Last Known Institution | Brigham and Women's Hospital |
| OpenAlex ID | https://openalex.org/A5054830306 |
| ORCID iD | 0000-0003-3698-9597 |
| Works | 2,111 |

## Researcher papers

Showing 12 of 84.

- [Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology](https://scholariq.org/papers/recommendations-for-chamber-quantification-a-report-from-the-american-society-of/)
- [Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography](https://scholariq.org/papers/guidelines-for-the-echocardiographic-assessment-of-the-right-heart-in-adults-a/)
- [Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction](https://scholariq.org/papers/dapagliflozin-in-patients-with-heart-failure-and-reduced-ejection-fraction/)
- [Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-versus-enalapril-in-heart-failure/)
- [Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events](https://scholariq.org/papers/cardiac-resynchronization-therapy-for-the-prevention-of-heart-failure-events/)
- [Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis](https://scholariq.org/papers/patisiran-an-rnai-therapeutic-for-hereditary-transthyretin-amyloidosis/)
- [Spironolactone for Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/spironolactone-for-heart-failure-with-preserved-ejection-fraction/)
- [Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction](https://scholariq.org/papers/dapagliflozin-in-heart-failure-with-mildly-reduced-or-preserved-ejection/)
- [Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both](https://scholariq.org/papers/valsartan-captopril-or-both-in-myocardial-infarction-complicated-by-heart/)
- [Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-in-heart-failure-with-preserved-ejection/)
- [Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome](https://scholariq.org/papers/lixisenatide-in-patients-with-type-2-diabetes-and-acute-coronary-syndrome/)
- [Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19](https://scholariq.org/papers/renin-angiotensin-aldosterone-system-inhibitors-in-patients-with-covid-19/)

## Researcher topics

- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Cardiac pacing and defibrillation studies](https://scholariq.org/topics/cardiac-pacing-and-defibrillation-studies/)
- [Cardiac Imaging and Diagnostics](https://scholariq.org/topics/cardiac-imaging-and-diagnostics/)

## Researcher university

- [Brigham and Women's Hospital](https://scholariq.org/institutions/brigham-and-women-s-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.